Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
Authors
Keywords
Receptor, IGF type 1, Receptor, Insulin, mTOR inhibitor, Drug resistance, Neoplasm, Breast neoplasms/drug therapy, Aromatase inhibitors/therapeutic use, Disease models, Animal
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-10-20
DOI
10.1186/s12885-016-2847-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Can we unlock the potential of IGF-1R inhibition in cancer therapy?
- (2014) Helen King et al. CANCER TREATMENT REVIEWS
- Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
- (2014) S. Di Cosimo et al. CLINICAL CANCER RESEARCH
- Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
- (2013) John FR Robertson et al. LANCET ONCOLOGY
- Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment
- (2012) D. H. Fagan et al. CANCER RESEARCH
- Quantifying insulin receptor isoform expression in FFPE breast tumors
- (2012) Sean C. Harrington et al. GROWTH HORMONE & IGF RESEARCH
- Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
- (2012) D. Yee JNCI-Journal of the National Cancer Institute
- Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody
- (2012) Jun Gyu Kim et al. PLoS One
- Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
- (2011) X. Hou et al. CANCER RESEARCH
- Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2
- (2011) H. K. Bid et al. MOLECULAR CANCER THERAPEUTICS
- The IGF Pathway Regulates ERα through a S6K1-Dependent Mechanism in Breast Cancer Cells
- (2011) Marc A. Becker et al. MOLECULAR ENDOCRINOLOGY
- The Insulin Receptor: A New Target for Cancer Therapy
- (2011) Roberta Malaguarnera et al. Frontiers in Endocrinology
- Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
- (2010) D. B. Ulanet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Generation of T Cells from Human Embryonic Stem Cell-Derived Hematopoietic Zones
- (2009) F. Timmermans et al. JOURNAL OF IMMUNOLOGY
- Targeting insulin and insulin-like growth factor signalling in oncology
- (2008) Michael Pollak CURRENT OPINION IN PHARMACOLOGY
- HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
- (2008) P. Haluska et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started